Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(14%)
Results Posted
33%(1 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_1
3
43%
Ph phase_3
1
14%
Ph phase_2
3
43%

Phase Distribution

3

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
unknown2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (42.9%)
Phase 23 (42.9%)
Phase 31 (14.3%)

Trials by Status

unknown229%
completed343%
recruiting114%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_2

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

NCT04533464
unknownphase_3

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study

NCT03545607
unknownphase_2

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

NCT04367077
completedphase_1

A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

NCT02611609
terminatedphase_1

Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation

NCT01841632
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04533464Phase 2

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Recruiting
NCT03545607Phase 3

MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study

Unknown
NCT04367077Phase 2

MultiStem Administration for COVID-19 Induced ARDS (MACoVIA)

Unknown
NCT02611609Phase 1

A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

Completed
NCT01841632Phase 1

Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation

Terminated
NCT01436487Phase 2

Study to Examine the Effects of MultiStem in Ischemic Stroke

Completed
NCT00677859Phase 1

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7